Home  |  Contact

UniProtKB/Swiss-Prot P04637: Variant p.Gly105Cys

Cellular tumor antigen p53
Gene: TP53
Chromosomal location: 17p13.1
Variant information

Variant position:  105
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Glycine (G) to Cysteine (C) at position 105 (G105C, p.Gly105Cys).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from glycine (G) to medium size and polar (C)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Involvement in disease:  Li-Fraumeni syndrome (LFS) [MIM:151623]: An autosomal dominant familial cancer syndrome that in its classic form is defined by the existence of a proband affected by a sarcoma before 45 years with a first degree relative affected by any tumor before 45 years and another first degree relative with any tumor before 45 years or a sarcoma at any age. Other clinical definitions for LFS have been proposed and called Li-Fraumeni like syndrome (LFL). In these families affected relatives develop a diverse set of malignancies at unusually early ages. Four types of cancers account for 80% of tumors occurring in TP53 germline mutation carriers: breast cancers, soft tissue and bone sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. Less frequent tumors include choroid plexus carcinoma or papilloma before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers. {ECO:0000269|PubMed:10484981, ECO:0000269|PubMed:1565144, ECO:0000269|PubMed:1737852, ECO:0000269|PubMed:1933902, ECO:0000269|PubMed:1978757, ECO:0000269|PubMed:2259385, ECO:0000269|PubMed:7887414, ECO:0000269|PubMed:8825920, ECO:0000269|PubMed:9452042}. Note=The disease is caused by mutations affecting the gene represented in this entry.
The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:  In LFS; germline mutation and in sporadic cancers; somatic mutation.
Any additional useful information about the variant.



Sequence information

Variant position:  105
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  393
The length of the canonical sequence.

Location on the sequence:   PAPAPSWPLSSSVPSQKTYQ  G SYGFRLGFLHSGTAKSVTCT
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         PAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCT

                              PGPAPSWPLSSSVPSPKTYPGTYGFRLGFLHSGTAKSVTWT

Rhesus macaque                PAPAPSWPLSSSVPSQKTYHGSYGFRLGFLHSGTAKSVTCT

Mouse                         PAPATPWPLSSFVPSQKTYQGNYGFHLGFLQSGTAKSVMCT

Rat                           PASATPWPLSSSVPSQKTYQGNYGFHLGFLQSGTAKSVMCT

Pig                           PAPATSWPLSSFVPSQKTYPGSYDFRLGFLHSGTAKSVTCT

Bovine                        PAPATSWPLSSFVPSQKTYPGNYGFRLGFLQSGTAKSVTCT

Rabbit                        PAPATSWPLSSSVPSQKTYHGNYGFRLGFLHSGTAKSVTCT

Sheep                         LAPATSWPLSSFVPSQKTYPGNYGFRLGFLHSGTAKSVTCT

Cat                           PAPAISWPLSSFVPSQKTYPGAYGFHLGFLQSGTAKSVTCT

Chicken                       PPTPPRAAPSPVVPSTEDYGGDFDFRVGFVEAGTAKSVTCT

Xenopus laevis                NAVPTV--TSCAVPSTDDYAGKYGLQLDFQQNGTAKSVTCT

Zebrafish                     QPQPSTLPPTSTVPETSDYPGDHGFRLRFPQSGTAKSVTCT

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 393 Cellular tumor antigen p53
DNA binding 102 – 292
Region 1 – 320 Interaction with CCAR2
Region 66 – 110 Interaction with WWOX
Region 100 – 370 Interaction with HIPK1
Region 100 – 300 Required for interaction with ZNF385A
Site 120 – 120 Interaction with DNA
Modified residue 120 – 120 N6-acetyllysine; by KAT6A
Alternative sequence 1 – 132 Missing. In isoform 7, isoform 8 and isoform 9.
Turn 105 – 108


Literature citations

No reference for the current variant in UniProtKB/Swiss-Prot.

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.